Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 07/17/2026 | CALL | $490.00 | 404 | +96 | +31.17% |
| 07/17/2026 | PUT | $440.00 | 386 | +91 | +30.85% |
| 09/18/2026 | CALL | $540.00 | 69 | +49 | +245.00% |
| 06/18/2026 | CALL | $465.00 | 78 | +47 | +151.61% |
| 07/17/2026 | CALL | $500.00 | 179 | +40 | +28.78% |
| 07/24/2026 | CALL | $460.00 | 36 | +36 | |
| 06/18/2026 | PUT | $440.00 | 198 | -15 | -7.04% |
| 06/18/2026 | PUT | $450.00 | 589 | -15 | -2.48% |
| 07/24/2026 | PUT | $350.00 | 56 | -15 | -21.13% |
| 06/18/2026 | CALL | $460.00 | 484 | -34 | -6.56% |
| 07/31/2026 | PUT | $350.00 | 55 | -35 | -38.89% |
| 06/18/2026 | CALL | $450.00 | 571 | -37 | -6.09% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.94% | 7.53M | 2.18B |
| Vanguard 500 Index Fund | 2.21% | 5.66M | 1.64B |
| Vanguard Specialized-Health Care Fund | 1.82% | 4.66M | 1.35B |
| Growth Fund Of America Inc | 1.74% | 4.46M | 1.29B |
| Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.45% | 3.72M | 1.08B |
| Invesco ETF Tr-Invesco NASDAQ 100 ETF | 1.44% | 3.69M | 1.07B |
| New Perspective Fund Inc | 1.15% | 2.94M | 852.45M |
| Fidelity Contrafund Inc | 1.10% | 2.83M | 820.18M |
| SPDR S&P 500 ETF Trust | 1.07% | 2.74M | 794.52M |
| Fidelity 500 Index Fund | 1.06% | 2.71M | 786.56M |
| iShares Core S&P 500 ETF | 0.88% | 2.27M | 657.44M |
| AB Large Cap Growth Fund | 0.81% | 2.08M | 603.8M |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.74% | 1.89M | 548.97M |
| American Balanced Fund | 0.73% | 1.86M | 539.44M |
| MFS Series Trust II-MFS Growth Fund | 0.67% | 1.71M | 496.09M |
| Loomis Sayles Growth Fund | 0.61% | 1.57M | 455.67M |
| Legg Mason Clearbridge Aggressive Growth Fd | 0.54% | 1.39M | 404.07M |
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
06/11 12:20 pm
Benzinga
Read moreKyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
06/08 02:34 pm
The Motley Fool
Read moreCRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
06/03 12:30 pm
The Motley Fool
Read moreCRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
05/31 12:11 pm
The Motley Fool
Read moreBetter Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
05/25 08:35 pm
The Motley Fool
Read more1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
05/11 04:15 pm
The Motley Fool
Read moreGlobal Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight
05/11 01:00 pm
GlobeNewswire Inc.
Read moreIs This Millionaire-Maker Biotech Stock a Buy Right Now?
05/06 03:30 am
The Motley Fool
Read moreGot $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?
05/02 03:30 am
The Motley Fool
Read moreWant to Build Real Wealth in Healthcare? These Stocks Are Worth Considering
04/30 06:10 am
The Motley Fool
Read moreWhat's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
04/30 05:10 am
The Motley Fool
Read moreShould You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?
04/30 03:10 am
The Motley Fool
Read moreIgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
04/29 01:00 pm
GlobeNewswire Inc.
Read more3 Healthcare Stocks With the Most Durable Competitive Moats
04/23 04:05 am
The Motley Fool
Read moreCRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
04/21 01:30 pm
The Motley Fool
Read moreIs Vertex Pharmaceuticals' Empire in Trouble?
04/16 03:26 pm
The Motley Fool
Read moreBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
04/10 09:55 am
Benzinga
Read moreGlobal DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications
04/07 01:44 pm
GlobeNewswire Inc.
Read moreIdiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight
04/06 01:00 pm
GlobeNewswire Inc.
Read moreWhere Will Vertex Pharmaceuticals Be in 1 Year?
03/25 04:02 pm
The Motley Fool
Read moreAnti-Aging Protein Research Takes a Step Forward with Cell Cloning
03/24 11:05 am
Benzinga
Read moreCRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?
03/23 01:30 pm
The Motley Fool
Read moreMy Top 3 Drug Stocks for March 2026
03/20 06:30 am
The Motley Fool
Read moreBest Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals
03/19 02:30 pm
The Motley Fool
Read moreUNCF NEW ENGLAND Raises Record-Breaking $800,000 for HBCUs and Student Success
03/19 07:00 am
GlobeNewswire Inc.
Read moreIs Vertex Pharmaceuticals Heading to $600?
03/15 09:15 pm
The Motley Fool
Read moreOil Crashes 10%, Stocks Rebound On Trump End-Of-War Signals: What's Moving Markets Tuesday?
03/10 01:03 pm
Benzinga
Read moreVertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps
03/10 09:24 am
Benzinga
Read more2 Biotech Giants to Buy in 2026
03/05 09:15 am
The Motley Fool
Read moreForget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of
03/04 02:23 pm
The Motley Fool
Read moreAbsci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
03/03 09:00 am
GlobeNewswire Inc.
Read more2 Top Healthcare Stocks to Buy in February
02/26 03:15 pm
The Motley Fool
Read moreForget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline
02/26 02:30 pm
The Motley Fool
Read moreThe Ultimate Biotech Stock to Buy With $500 Right Now
02/24 04:30 am
The Motley Fool
Read moreCould Vertex Stock Help Turn $100,000 Into $1 Million by 2036?
02/22 07:30 pm
The Motley Fool
Read moreCRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
02/20 11:22 am
Investing.com
Read moreThe Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026
02/13 04:10 pm
The Motley Fool
Read moreSmall Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?
02/13 02:48 pm
Benzinga
Read moreCRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
02/13 02:45 pm
Benzinga
Read more1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell
02/10 02:15 pm
The Motley Fool
Read moreShould You Buy Vertex Before Feb. 12?
02/10 10:35 am
The Motley Fool
Read moreTargeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica
02/03 02:56 am
GlobeNewswire Inc.
Read moreAutologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica
01/27 02:43 pm
GlobeNewswire Inc.
Read moreBreaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
01/23 01:56 pm
GlobeNewswire Inc.
Read moreStock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%
01/15 06:27 pm
The Motley Fool
Read morePrediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
01/14 12:15 pm
The Motley Fool
Read morePrediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
01/09 10:30 am
The Motley Fool
Read moreEntrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
01/08 08:00 am
GlobeNewswire Inc.
Read moreMy 10 Top Stocks to Buy to Start the New Year Off Right
01/05 09:15 pm
The Motley Fool
Read moreGene Therapy: 5 Biotech Stocks Chasing the $36B Prize
01/02 02:29 pm
Benzinga
Read more